Advanced Cancer Clinical Trial
Official title:
Phase I/IIa First-In-Human Study of EOS884448 in Participants With Advanced Cancers.
Verified date | September 2021 |
Source | iTeos Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
IO-002 study is a multicenter, open-label, dose-escalation Phase I/IIa clinical study to evaluate the safety and tolerability, PK, PD, and antitumor activity of EOS884448 in participants with advanced cancers.
Status | Completed |
Enrollment | 40 |
Est. completion date | April 7, 2022 |
Est. primary completion date | April 7, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Be willing to provide a signed written informed consent for the trial and consent for biopsies before and during administration of EOS884448 2. Be more than18 years of age on day of signing informed consent. 3. Have histologically or cytologically confirmed advanced or metastatic cancer for whom no standard treatment is further available 4. Have evaluable disease, per RECIST v1.1 for solid tumor escalation or other criteria if indicated 5. Have an ECOG performance status of Grade 0 to 1. 6. Have adequate organ function. 7. Agree to use adequate contraception during the treatment if required. Exclusion Criteria: 1. Has received any anti-cancer therapy, unless at least 4 weeks (or 5 half-lives, whichever is shorter) since the last dose. 2. Has undergone major surgery within 5 weeks before initiating treatment. 3. Has received prior radiotherapy within 2 weeks of start of IP. 4. Has toxicity (except for alopecia) related to prior anti-cancer therapy, unless the toxicity is resolved, returned to baseline or Grade 1, or deemed irreversible. 5. Has known CNS metastases. 6. Has any condition requiring concurrent use of systemic immunosuppressants or corticosteroids. 7. Has uncontrolled or significant cardiovascular disease. 8. Has received vaccine containing live virus within 4 weeks. 9. Has known active or chronic viral hepatitis. 10. Has any known or underlying medical, psychiatric condition, and/or social situations that, in the opinion of the investigator, would limit compliance with study requirements. |
Country | Name | City | State |
---|---|---|---|
Belgium | GZA Ziekenhuizen campus Sint-Augustinus | Antwerp | |
Belgium | Cliniques universitaires St Luc-UCL | Brussels | |
Belgium | Institut Jules Bordet | Brussels | |
Belgium | Universitair Ziekenhuis Gent | Gent |
Lead Sponsor | Collaborator |
---|---|
iTeos Belgium SA |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of participants with Adverse Events | From first dose date to 90 days after the last dose (up to 48 weeks) | ||
Primary | Percentage of participants who experience a Dose Limiting Toxicity | From first study treatment administration through Day 28 | ||
Primary | Define the recommended Phase 2 dose (RP2D) of EOS884448 in participants with advanced tumors. | up to 48 weeks | ||
Secondary | Mean and median Area under the curve (AUC) of EOS884448 at each dose level | up to 48 weeks | ||
Secondary | Mean and median Maximum concentration (Cmax) of EOS884448 at each dose level | up to 48 weeks | ||
Secondary | Percentage of participants with Objective Response as determined by Investigator according to RECIST v1.1or per other specific response criteria according to their tumor type. | From study enrollment until participant discontinuation, first occurrence of progressive disease, or death from any cause, whichever occurs first (approximately 48 weeks) | ||
Secondary | Percentage of participants with anti-drug antibodies to EOS884448 | Recorded at baseline (screening), during the first 4 cycles of treatment (4 months), at end of treatment, and 30 and 90 days post last dose (approximately 48 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 |